Overview

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled. There will be a treatment period (through Week 24) and a follow up period (where TEPEZZA will not be infused).
Phase:
Phase 4
Details
Lead Sponsor:
Horizon Therapeutics USA, Inc.